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Abstract
Dengue is the most prevalent mosquito-borne viral disease of humans and is caused by the
four serotypes of dengue virus. To estimate the incidence of dengue and other arboviruses,
we analyzed the baseline and first year follow-up of a prospective school-based cohort
study and their families in three cities in the state of Yucatan, Mexico. Through enhanced
surveillance activities, acute febrile illnesses in the participants were detected and yearly
blood samples were collected to evaluate dengue infection incidence. A Cox model was fit-
ted to identify hazard ratios of arboviral infections in the first year of follow-up of the cohort.
The incidence of dengue symptomatic infections observed during the first year of follow-up
(2015–2016) was 3.5 cases per 1,000 person-years (95% CI: 1.9, 5.9). The incidence of
dengue infections was 33.9 infections per 1,000 person-years (95% CI: 31.7, 48.0). The
majority of dengue infections and seroconversions were observed in the younger age
groups (� 14 years old). Other arboviruses were circulating in the state of Yucatan during
the study period. The incidence of symptomatic chikungunya infections was 8.6 per 1,000
person-years (95% CI: 5.8, 12.3) and the incidence of symptomatic Zika infections was 2.3
per 1,000 person-years (95% CI: 0.9, 4.5). Our model shows that having a dengue infection
during the first year of follow-up was significantly associated with being female, living in Ticul
or Progreso, and being dengue naïve at baseline. Age was not significantly associated with
the outcome, it was confounded by prior immunity to dengue that increases with age. This is
the first report of a cohort in Latin America that provides incidence estimates of the three
arboviruses co-circulating in all age groups. This study provides important information for
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understanding the epidemiology of dengue and other arboviruses and better informing pub-
lic health policies.
Author summary
Dengue is a major public health problem worldwide. The burden of dengue in Latin
America is been increasing in the last years and Mexico is one of the countries with the
highest burden in this region. To better understand the transmission of dengue in Mexico
we established a school-based prospective cohort study of dengue virus infection in chil-
dren and their families in three cities in the state of Yucatan, Mexico. In this article we
show that around 70% of the cohort population has prior immunity to dengue. Also that
the rate of dengue cases varied among cities and we also confirm the circulation of chi-
kungunya and Zika virus in the cohort participants during the first year of follow-up. We
found evidence that having prior dengue immunity might protect again Zika symptomatic
infections. The results of this study will be useful for the scientific community and policy
makers from Mexico and other countries in Latin America to properly plan and evaluate
control strategies and interventions like vector control and vaccines.
Introduction
Over the past 40 years, dengue virus incidence in human population has increased 30-fold
and the geographic range of the virus expanding to new countries as increasing urbanization,
global human travel and urban to rural migration enable opportunities for transmission [1, 2]
Currently more than 40% of the human population worldwide is at risk of dengue infections,
with approximately 390 million infections estimated to occur globally each year, of which 96
million have clinical manifestations of the virus [3].
Dengue virus (DENV) has four serotypes, each of them can be responsible for dengue epi-
demics and can also be associated with severe disease depending on the sequence and time
between infections, among other factors [4–6]. The clinical spectrum of dengue ranges from
asymptomatic infections to life-threatening severe disease; approximately 50% to 90% of den-
gue infections are asymptomatic [7, 8]. The probability of symptomatic dengue due to dengue
virus infection is altered by the previous dengue immune status [9]. Currently there is no spe-
cific treatment for dengue infection or clinical predictors to prevent severe disease [10].
Surveillance systems based on the monitoring and notification of dengue symptomatic
cases have low sensitivity and rarely detect low or sporadic transmission [11, 12]. The propor-
tion of dengue asymptomatic infections varies widely by populations, geographical areas, and
over different epidemiological periods [13]. Underreporting of dengue cases to national sur-
veillance systems hinders accurate local, regional and global estimation of disease burden [14].
Necessary steps to better understand dengue transmission in at-risk populations include
strengthening passive surveillance systems by incorporating active surveillance methods (e.g.,
house-to-house visits, school absenteeism or self-identification of fever episodes) and improv-
ing the detection of inapparent infections to rectify the underreporting of unspecified febrile
dengue infections.
Vector control remains the core strategy for the prevention of dengue [15, 16]. However,
current approaches that only temporarily affect mosquito populations have not been proven to
be sufficient to prevent dengue transmission [17]. Effective and sustainable dengue prevention
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and control requires innovation, by integrating and making optimal use of the most effective
control tools available like integrated vector management, and also the introduction of new
tools e.g. vaccines and other novel vector control technologies, especially in growing and com-
plex urban environments [18, 19].
Currently five vaccine candidates are in clinical stages of development [20]. Only one vac-
cine has completed two Phase III trials and it is being licensed for introduction in several
countries [21–23]. This vaccine has an estimated efficacy of 64.7% and 56.5% in the Latin
American and Southeast Asian trials, respectively and the efficacy was significantly higher in
participants with pre-existing dengue neutralizing antibodies compared to those who were
seronegative [21, 22, 24].
The availability of a licensed vaccine poses different challenges to current dengue control
programs since it is not expected to vaccinate all the susceptibles and at-risk populations or
even provide complete vaccine coverage in target groups. Vaccine introduction will therefore
be a gradual process. In each of these populations several questions need to be addressed
regarding the clinical spectrum and transmission risks in order to target vaccination to provide
the most benefit [25].
Thus, measuring the burden of disease attributable to dengue infection is imperative for
understanding the potential impact of dengue control interventions and feasibility for vaccine
introduction and evaluation. There are limited number of established longitudinal cohort
studies characterizing dengue infection in Latin America. The aim of this study was to estimate
age-specific attack rates, the proportion of inapparent infections, incidence rate ratios and
assessing the covariates associated with arboviral infections and symptomatic disease in a pro-
spective dengue cohort established in Yucatan, Mexico.
Methods
Settings
The state of Yucatan is located in the southeast peninsula of Mexico, bordering the Gulf of
Mexico and the Caribbean Sea. As described elsewhere, the cities of Merida, Progreso and
Ticul were selected as three settings with different epidemiological dynamics (low, medium,
high dengue transmission) (Table 1), based on their history of dengue outbreaks in the past
and the co-circulation of more than two serotypes in recent years [26]. Incidence rates of sus-
pected and confirmed cases from 1979 to 2013 were estimated for each city. As these three cit-
ies also have different dengue incidence rates, this allowed us to explore possible differences in
dengue transmission scenarios [27].
Merida, the capital city, is the largest urban center in the region with 830,732 inhabitants
(2016). The weather is warm and humid, the mean annual temperature is 25.9˚C (19.5 to 33.6)
and annual precipitation is 1050 (mm). The rainy season is from June to October. Progreso is
the main seaport in the state, 32 km away from Merida, with 54,000 inhabitants. This town has
similar weather conditions and is a weekend and holiday resort (July-August) for people living
Table 1. Characteristics of the study settings of the cohort in Yucatan, Mexico.
Merida Progreso Ticul
Population (inhabitants) 892,363 59,122 40,161
Number of households 257,826 16,020 9,808
Average yearly temperature (˚C) 25.9 25.4 26.4
Precipitation (mm) 1,050 466 1,229
Historical dengue risk High risk Medium risk Low risk
https://doi.org/10.1371/journal.pntd.0006847.t001
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in Merida, as well as a national and international tourist resort. Ticul is a town located 82 km
south of Merida with 34,000 inhabitants whose main economic activity is dedicated to shoe
manufacturing [28].
Selection of risk areas
The primary aim of this study was to characterize the local epidemiology and transmission
dynamics of dengue in the state of Yucatan, using a school-based, prospective cohort in the dif-
ferent transmission district by city, three criteria were adopted: 1) Proportion of epidemiologi-
cal weeks with reported symptomatic dengue cases compared to epidemiological weeks with
no reported cases; 2) Duration of the dengue epidemic waves as a proxy of persistent dengue
transmission; 3) Intensity of transmission measured as the incidence rate during the dengue
season.
The school-based study is defined by a random selection of five extensive geographic areas
(districts) with different dengue transmission risks (high, medium or low). The data obtained
from the epidemiological surveillance system identified those areas where dengue has been
historically higher and persistent and where the transmission risk is defined as high, medium
and low. The sample includes low-risk areas in Merida and Progreso, medium-risk areas in
Merida and Ticul, and a high-risk area in Merida. The sample size was estimated for the
school-children from each transmission risk by city. The sample size was 150 school children
from each transmission risk by city and then expanded to their families.
Each area of transmission included several primary public schools from which the cohort of
children from first to third grade was randomly selected. The randomization was done using
stratified random sampling. First, we stratified the transmission risk of the neighborhoods on
the three cities (Merida, Progreso and Ticul). These included two low-risk areas (one in the
north of Merida and one in Progreso); two medium risk areas (one urban area in central
Merida and one in Ticul); and one high-risk urban area in the south of Merida. The risk was
defined based on historical epidemiological features: 1) the historical dengue cases reported to
the epidemiological surveillance system; 2) the percent of cases reported every year in each set-
ting; and 3) the continuous transmission during 6 to 8 or more weeks every year. Second, after
selecting some areas randomly based on the transmission risk, the field team asked for the list
of all the schools located on the randomized transmission settings and a simple random sam-
pling procedure was done to select the schools. The next step was done with the list of the stu-
dents from 1st to 4th grade from each school that were also randomized.
Recruitment and enrollment
Children were enrolled at the beginning of the academic year from first through third grade (6
to 8 years old) and were eligible to remain in the study until they graduated from sixth grade
(12 years-old). The only exclusion criterion was intent to move outside of the study area dur-
ing the twelve months following enrollment. The students entering elementary school and
those in second and third grade were selected and included in the cohort study with written
consent granted by their parents. Each group of enrolled children and their respective families
were followed-up during their education track for the period of the study. Families were
defined for this study as people living in the same household (with minimum of five nights
sleping in the household) but not necessary that belong to the same family (blood relation).
The strategy of establishing and maintaining a cohort of individuals and their families in a
long-term project requires ongoing effort. Success of such projects requires sharing interim
results, advances in the project, and deep understanding of the community-level protective
measures against dengue epidemics. Therefore, each site had a team of community specialists
Baseline and first year follow-up in a dengue cohort in Yucatan, Mexico
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006847 November 21, 2018 4 / 20
consisting of local physicians, nurses, laboratory technicians, microbiologists, and anthropolo-
gists who gathered information and organized activities directed to sensitize and educate
cohort members and their families about dengue epidemiology and control.
Follow-up visits
We obtained demographic information and blood samples from the entire study population at
baseline and an annual blood sample. The study participants and their families were followed
from January 2015 through October 2016 at 12-month intervals for serological evidence of
dengue infection after the dengue season every year. Blood samples were taken during the sur-
veillance period each year (January-July) right after the typical dengue transmission season.
Participants were considered lost to follow-up if a full year had passed since their previous
blood draw, despite repeated attempts to locate the participant, or if there was a verifiable rea-
son for dropping them from the study (e.g., direct request from the participant, movement
from the study area, or death).
During the follow-up period the infection rates in different age groups were measured as
well as the proportion of inapparent infections or underreporting of febrile cases during the
dengue season. The prospective follow-up of the school cohort and their families also provided
information for the estimation of age group hazards of infection for those represented in this
sample.
Enhanced surveillance. The enhanced surveillance was used to identify dengue acute
febrile cases in the cohort through absentee surveillance at school and its surrounding area,
and also from the Mexican national surveillance system.
In addition to weekly school visits to investigate school absenteeism there was continuous
active surveillance for febrile cases in all the cohort participants using mobile applications and
a dengue toll free phone number (1-800). The mobile application was used by the staff of the
study to collect the socio-demographic and geographic information for each participant at
enrollment and during the periodic visits to the households. The toll free phone was a 24/7
phone line ready to receive reports of febrile cases that met the case definition of dengue for
the protocol. Every call received on this toll free phone that suggested a dengue case triggered
a visit to the family by a physician from the study who activated the procedures described on
the study protocol to detect dengue infections. Also the families were advise to report hospital-
izations and any changes on the address of the participants of the cohort.
The cohort participants were followed closely for all febrile illnesses, and children and their
relatives who also had fever were screened clinically and by laboratory testing, for signs and
symptoms of dengue. The surveillance system identified suspected or probable dengue cases
that were clinically and serologically studied to confirm dengue infection. During school vaca-
tion (July-August and December-March), children were visited or contacted weekly at their
homes. During the annual follow-up visits, the field team collected blood samples from all the
participants of the study who consented to give the blood sample in order to detect inapparent
infections in the cohort.
A person was considered to have an inapparent (subclinical) dengue infection when their
serum sample tested positive for IgM antibody to any dengue serotype without an accompa-
nying febrile illness or school-absence identified during the active surveillance period or if the
cohort participant seroconverted in the annual follow-up samples. Clinical definitions of sero-
logically or virologically confirmed dengue infection were based on evidence of acute dengue
infection, as described below.
Case definitions. Symptomatic dengue infection was classified as symptomatic non-hos-
pitalized or symptomatic hospitalized, based on admission into the hospital as decided by the
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treating physician. Hospitalized symptomatic cases were further defined as either dengue or
severe dengue using the 2009 guidelines from the World Health Organization [1].
Dengue case definition. Dengue cases were classified according to the 2009 WHO Case Clas-
sification [1].
Dengue without warning signs. Dengue without warning signs is defined by acute fever
(� 38.5˚) and two or more of the following symptoms: headache, myalgia, arthralgia, retroor-
bital pain, rash, hemorrhagic manifestations or leukopenia [1].
Dengue with warning signs. Dengue fever with any of the following warning signs: abdomi-
nal pain, persistent vomiting, fluid accumulation, lethargy, mucosal bleeding, fluid accumula-
tion, liver enlargement, or increasing hematocrit with decreasing platelets [1].
Severe dengue. Dengue fever with any of the following: severe bleeding, severe plasma
leakage leading to shock or fluid accumulation with respiratory distress, or organ failure or
involvement as evidenced by liver enzymes� 1, 000, impaired consciousness, failure of the
heart or other organs [1].
Laboratory criteria for confirmation for dengue. Acute dengue case. A symptomatic par-
ticipant with less than 7 days of onset of symptoms who tested positive for dengue evidenced
by: 1) detection of dengue NS1 antigen, 2) detection of IgM antibodies to dengue virus by
ELISA, 3) detection of IgG capture antibodies to dengue virus, or 4) detection of DENV RNA
by Trioplex Real-time RT-PCR [29–34].
Inapparent dengue infection. A participant whose paired annual serum samples demon-
strated seroconversion by four-fold increase on IgG antibodies and who did not experience a
symptomatic dengue infection during the time of follow-up [29, 35–37].
Primary dengue infections. A dengue infection is classified as a primary DENV infection if
seroconversion was observed [38]. First DENV infections were identified by counting the
number of the infections documented in a participant who entered the cohort dengue-naïve,
and whose paired annual sample were positive for anti-DENV IgG antibodies [29, 37, 38].
Dengue prior exposure. Dengue-naïve. A participant who did not have detectable anti-
DENV antibody at enrollment when their sample was tested using a Dengue IgG Indirect
ELISA.
Dengue non-naïve. A participant who had detectable anti-DENV antibody at enrollment
when their sample was tested using a Dengue IgG Indirect ELISA at enrollment [29, 37, 38].
Chikungunya case definition
Acute chikungunya symptomatic infection. A participant with the presence of all these
signs and symptoms: abrupt onset of fever� 38.5˚ accompanied by joint pain, muscle pain,
headache, nausea, fatigue and rash [39].
Laboratory criteria for confirmation for chikungunya. A symptomatic participant who
tested positive for chikungunya evidenced by: 1) detection of CHIKV RNA by RT-PCR or
Real-time RT-PCR, or 2) enzyme-linked immunosorbent assays (ELISA) confirmed anti-chi-
kungunya IgM antibodies [39].
Zika case definition
Zika virus disease. Patient with rash and two or more of the following signs or symptoms:
fever, usually� 38.0˚, conjunctivitis (non-purulent/hyperemic), arthralgia or myalgia [40, 41].
Laboratory criteria for Zika confirmation. Participant who met the criteria for a sus-
pected case AND had laboratory confirmation of Zika virus RNA in serum or urine by Real-
time RT-PCR [42]. For ZIKV diagnosis, serological tests like IgM ELISA were not used in this
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study to confirm ZIKV disease due to the cross-reactivity of the tests available with other flavi-
viruses circulating in the region like DENV [43, 44].
Ethics statement
This study was conducted as a collaboration between the Ministry of Health of Yucatan,
Mexico and the Center for Inference and Dynamics of Infectious Diseases in Seattle, WA,
USA. This study was approved by the Institutional Review Boards at Fred Hutchinson Cancer
Research Center, Seattle, WA, USA and the General Hospital Agustin O’Horan, Health Ser-
vices of Yucatan, Mexico. Written consent was obtained from all adult participants (>18 years
old) after providing them with a detailed explanation of the study and procedures. Parents/
guardians of all child participants (� 18 years old) were asked to provide written consent on
their behalf. The analysis using de-identified data was approved at Fred Hutchinson Cancer
Research Center.
Statistical analysis
The age-specific baseline seroprevalence for dengue virus was estimated for the entire cohort.
For the first year of follow-up, the follow-up time was estimated as the time between enroll-
ment and the end of the reported study period (August 2016), or withdrawal from the study.
For those who were lost to follow-up, person-years were calculated as the time between enroll-
ment and the last contact with study personnel, plus one-half the time between the last contact
and the date recorded as lost to follow-up.
The analysis of dengue infections was limited to those participants who completed the year
and contributed a blood sample at the beginning and the end of the year. In order to provide
estimates of dengue infection incidence, since the exact timing of the dengue infection could
not always be ascertained, persons who experienced a dengue infection in the first year of
follow-up contributed person-time for that entire year. For the analysis of dengue infections,
the age of the participant was defined as the age when their annual sample was collected. The
crude incidence per 1,000 person-years was 1,000 times the number of dengue infections
divided by the number of person-years in the dataset as published elsewhere [29, 35, 45].
The incidence rate ratio was also estimated for each arboviral infection comparing dengue
non-naïve and dengue naïves [46–48]. The hazard ratios (HRs) and 95% confidence intervals
(95% CIs) for dengue and other arboviral infections were estimated using a Cox proportional
hazards model and adjusting for potential confounders such as age, gender, city, and prior
exposure to dengue [48, 49]. All the statistical analyses were done in R, version 3.2.1 [50].
Results
Baseline characteristics of the participants
A total of 767 families encompassing 3,400 participants were enrolled from January to June,
2015 across the three sites in Yucatan. The majority of the families and participants were from
Merida (2,021 (59.4%), followed by Ticul (738 (21.7%) and Progreso (641(18.9%) (Fig 1).
Among the participants 1,869 (55.0%) were females, 1,463 (43.0%) were 14 years old or youn-
ger, and 2,970 (87.4%) of them were born in the state of Yucatan (Table 2). These participants
contributed with 3430.87 person-years for the first year of follow-up. The mean participation
time is 1.01 years (368.31 days) per participant (range 0.04–1.94).
A total of 1,096 (32.2%) participants did not complete the first year of follow-up. A total of
320 (29.3%) of the participants were classified as lost to follow-up (the team lost track of the
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participant and the family), 210 (19.2%) moved out of the state of Yucatan and 564 (52.0%)
asked for voluntary withdrawal from the study (Fig 1).
Dengue baseline seroprevalence
The baseline seroprevalence was estimated using samples from 2,853 participants who autho-
rized a blood sample collection at enrollment. The overall baseline dengue seroprevalence in
Fig 1. Flowchart of participants in the dengue cohort, Yucatan, Mexico.
https://doi.org/10.1371/journal.pntd.0006847.g001
Table 2. Demographic characteristics of the enrolled cohort population from Yucatan, Mexico in 2015 (N = 3,400).
Variable Merida (N = 2,021) Progreso (N = 641) Ticul (N = 738) Total
Age (Years)
<8 593 (29.3%) 188 (29.3%) 198 (26.8%) 979 (28.8%)
9–14 289 (14.3%) 86 (13.4%) 109 (14.8%) 484 (14.2%)
15–19 85 (4.2%) 33 (5.2%) 40 (5.4%) 158 (4.7%)
20–49 842 (41.7%) 277 (43.2%) 337 (45.7%) 1456 (42.8%)
>50 212 (10.5%) 57 (8.9%) 54 (7.3%) 323 (9.5%)
Gender
Male 917 (45.4%) 286 (44.6%) 328 (44.4%) 1531(45.0%)
Female 1104 (54.6%) 355 (55.4%) 410 (55.6%) 1869 (55.0%)
Number of families 463 (60.3%) 153 (20.0%) 151 (19.7%) 767 (100%)
Average number of people per family (Range) 4.36 (2,11) 4.18 (2,11) 4.88 (2,16) 4.43
Born in Yucatan
Yes 1775 (87.8%) 550 (85.8%) 645 (87.4%) 2970 (87.4%)
No 129 (6.4%) 52 (8.1%) 46 (6.2%) 227 (6.7%)
No information 117 (5.8%) 39 (6.1%) 47 (6.4%) 203 (6.0%)
Withdrawn (No follow-up)
Yes 778 (38.5%) 123 (19.2%) 195 (26.4%) 1096 (32.2%)
No 1243 (61.5%) 518 (80.8%) 543 (73.6%) 2304 (67.8%)
https://doi.org/10.1371/journal.pntd.0006847.t002
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the cohort was 70.28% (95% CI 68.6%–72%) indicating that most of the population had
already been exposed to at least one dengue infection (Fig 2).
The cohort from Ticul had the highest seroprevalence (81.1%), followed by Merida (70.2%)
and Progreso (57.9%). The differences in seroprevalence estimates by city were statistically sig-
nificant (p<0.001). Dengue seroprevalence increased with age, and females in the cohort had
significantly higher seroprevalence estimates compared with males (p = 0.04) (Table 3).
Suspected symptomatic arboviral cases
In the time period after enrollment and the collection of the baseline blood sample to
the first annual follow-up of the cohort, 199 suspected arbovirus infection cases or
Fig 2. Age-specific baseline dengue seroprevalence in the cohort, Yucatan, Mexico. A. Overall dengue
seroprevalence of the cohort by age. B. Dengue seroprevalence of the cohort in Merida by age. C. Dengue
seroprevalence of the cohort in Progreso by age. D. Dengue seroprevalence of the cohort in Ticul by age.
https://doi.org/10.1371/journal.pntd.0006847.g002
Table 3. Baseline dengue seroprevalence of enrolled cohort of participants from Yucatan, Mexico, in 2015, by city, age and gender (n = 2,853).
Baseline exposure Dengue-naïve (n = 829) Dengue non-naïve (n = 2005) Indeterminate (n = 19) Total
City
Merida 490 (29.2%) 1178 (70.2%) 10 (0.6%) 1678
Progreso 226 (41.7%) 313 (57.9%) 2 (0.4%) 541
Ticul 113 (17.8%) 514 (81.1%) 7 (1.1%) 634
Age (Years)
� 8 484 (59.0%) 329 (40.1%) 8 (1.0%) 821
9–14 184 (41.7%) 253 (57.4%) 4 (0.9%) 441
15–19 37 (29.8%) 86 (69.4%) 1 (0.8%) 124
20–49 109 (8.6%) 1149 (90.9%) 6 (0.5%) 1264
� 50 15 (7.4%) 188 (92.6%) 0 (0%) 203
Gender
Male 416 (34.0%) 792 (64.8%) 14 (1.2%) 1222
Female 413 (25.3%) 1213 (74.4%) 5 (0.3%) 1631
https://doi.org/10.1371/journal.pntd.0006847.t003
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undifferentiated febrile illnesses were identified in the study population of 3,400. The most
common clinical diagnosis was undifferentiated fever (105 cases (52.76%)), followed by 76
(38.19%) suspected dengue cases, 17 (8.54%) suspected chikungunya cases and one suspected
case of Zika. (Table 4). The dengue incidence rate for suspected cases was 21.86 per 1,000
person-years. From the 199 samples tested, 148 (74.4%) were negative for dengue, chikungu-
nya y Zika.
All the consultations were in the outpatient clinic. The most common symptoms presented
by the cohort population were: fever, headache, myalgia, arthralgia, rash and conjunctivitis.
No significant differences in symptoms were found among all the arboviral clinical diagnoses
(p = 0.560). No severe symptoms were identified in the study population.
As the symptoms were non-specific across the different arboviral infections, we estimated
the incidence of arbovirus suspected cases to be 58.02 per 1,000 person years.
Confirmed arboviral symptomatic infections
A total of 199 participants with suspected arbovirus symptomatic infections or undifferenti-
ated febrile illnesses were identified in the 2935 participants of the cohort. These participants
contributed with 3236.48 person- years in the first annual follow-up. Among the symptomatic
arboviral infections 12 (6.0%) were laboratory-confirmed as dengue-positive, 30 (15.1%) as
chikungunya-positive, 8 (4.0%) as Zika-positive, and 148 (74.4%) were classified as fever of
unknown origin (Table 4). The overall incidence rate of arbovirus confirmed symptomatic
infections was 14.57 per 1,000 person-years (95% CI: 10.82, 19.21).
The incidence rate of confirmed symptomatic dengue was 3.45 cases per 1,000 person-years
(95% CI: 1.87, 5.86). In the first year of the study, 12 symptomatic acute dengue cases were ser-
otyped; DENV1 (52%) was the most isolated serotype, followed by serotype DENV4 (33.3%)
and DENV2 (16.7%). DENV3 was not isolated during the analyzed period. No hospitalizations
or deaths resulting from symptomatic dengue infection were reported during the first year of
the cohort. The highest incidence of dengue was observed in the participants in the following
groups: participants that were 15-19 years of age (IR: 6.88 per 1,000 person-years), females (IR:
6.3 per 1,000 person-years), and participants from Merida (IR: 4.2 per 1,000 person-years)
(Table 5). The incidence rate of confirmed symptomatic chikungunya was 8.62 cases per 1,000
person-years (95% CI: 5.81, 12.30). The highest incidence of chikungunya was observed in the
participants in the group 50 years old or older, females and in Ticul. (Table 5). The incidence
rate of confirmed symptomatic Zika was 2.33 cases per 1,000 person-years (95% CI: 0.99,
4.53). The highest incidence rate estimated for Zika was also in Ticul (7.32 per 1,000 person-
years). One case of co-infection of dengue and chikungunya was also identified. The majority
of cases occurred from August to December 2015 which is historically considered the dengue
season in Yucatan, Mexico. We explored the presence of clustering at the family level on this
Table 4. Arbovirus suspected cases by etiology in cohort participants in Yucatan, Mexico (N = 199).
Dengue Zika Chikungunya Indeterminate Negative Total
Probable symptomatic cases
Dengue 7 (58.3%) 1 (12.5%) 11 (36.7%) 1 (100%) 56 (37.8%) 76 (38.2%)
Chikungunya 1 (8.3%) 6 (75%) 0 0 10 (6.8%) 17 (8.5%)
Zika 1 (8.3%) 0 0 0 0 1 (0.5%)
Undifferentiated fever 3 (25%) 1 (12.5%) 19 (63.3%) 0 82 (55.4%) 105 (55.4%)
Total confirmed 12 8 30 1 148 199
https://doi.org/10.1371/journal.pntd.0006847.t004
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cohort but during this first year of follow-up in just one household were detected two dengue
cases so the adjustment for clustering was not needed.
Total dengue infections
For the analysis of dengue infections, we included only the participants who completed the
first year of follow-up and contributed with a blood sample at the beginning of the study (start-
ing in January 2015 through out 2015) and at the end of the first year of follow-up depending
on the day of enrollment (up to October 2016). Of these 1,890 participants, 1,037 (54.8%) were
from Merida, 379 (20.1%) were from Progreso and 474 (25.1%) were from Ticul. In total, these
1,890 participants contributed 2271.14 person-years and had 83 confirmed dengue infections,
for an incidence rate of 36.55 infections per 1,000 person-years (95%CI 29.29, 45.07) (Table 6).
From the total confirmed dengue infections, 14.5% (12/83) were confirmed using RT-PCR for
dengue and the rest 85.5% (71/86) were confirmed by serology according to the protocol. The
overall ratio of dengue infections to symptomatic cases was 8.22 dengue infections per dengue
symptomatic case. The highest incidence of dengue was observed in the participants in the
group of 15-19 years of age followed by the� 8 year olds. High incidence rates were also
observed in participants from Merida, females, and in the population of naïves (Table 6). The
lowest rates of symptomatic cases were in the oldest age group(� 50 years-old) and the 9 to 14
years-old group with a rate of 6.66 cases per 100 infections (Additional tables by age and city
can be found on the supplemental material S1 Table).
Primary dengue infections in the naïve population
Among the 829 participants who entered the cohort as dengue-naïve, 555 dengue-naïve par-
ticipants completed the first annual of follow-up and provided a blood sample. These partici-
pants contributed 560.5 person-years of time. Over the first year of follow-up, 74 dengue-
naïve participants experienced a primary dengue infection. The overall percent of serocon-
verting naïve individuals was 13.3%. The incidence rate of primary dengue infections was
132.0 infections per 1,000 person-years (95% CI: 104.4, 164.8). There were twice as many
seroconverting naïve individuals in Progreso (14.8%) and Merida (14.2%), as compared to
Ticul (7.7%) (Table 7).
Table 5. Incidence rates (IR) per 1,000 person-years of arbovirus confirmed symptomatic infections in the cohort in Yucatan, Mexico by age, gender, and city.
Person-years at risk (N) Dengue IR (95%CI) Chikungunya IR (95%CI) Zika IR (95%CI)
All participants 3430.9 (3400) 12 3.5 (1.9, 5.9) 30 8.6 (5.8, 12.3) 8 2.3 (0.9, 4.5)
Age groups (years)
� 8 1001.4 (991) 3 2.9 (0.6, 8.8) 10 9.9 (4.8, 18.4) 4 3.99 (1.1, 10.2)
9–14 502.5 (484) 1 1.9 (0.03, 11.1) 4 7.9 (2.1, 20.4) 2 3.9 (0.5, 14.4)
15–19 145.3 (146) 1 6.88 (0.1, 38.3) 1 6.9 (0.1, 38.3) 0 0)
20–49 1490.1 (1456) 7 4.7 (1.9, 9.7) 11 7.4 (3.7, 13.2) 2 1.3 (0.2, 4.9)
� 50 291.5 (323) 0 0 4 13.7 (3.7, 35.1) 0 0
Gender
Male 1511.7 (1531) 0 0 9 5.9 (5.8, 12.3) 3 1.9 (0.4, 5.8)
Female 1919.2 (1869) 12 6.3 (3.2,10.9) 21 10.9 (6.8, 16.7) 5 2.6 (0.8, 6.1)
City
Merida 2164.3 (2021) 9 4.2 (1.9, 7.9) 18 8.3 (4.9, 13.1) 2 0.9 (0.1, 3.3)
Progreso 601.8 (641) 2 3.3 (0.4, 12.0) 5 8.3 (2.7,19.3) 1 1.7 (0.02, 2.3)
Ticul 682.9 (738) 1 1.5 (0.02, 8.2) 7 10.3 (4.1, 21.1) 5 7.3 (2.4, 17.1)
https://doi.org/10.1371/journal.pntd.0006847.t005
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Incidence rate ratios of arbovirus confirmed symptomatic cases and
dengue infections
For the IRR estimations, we assumed as exposed group the population that was naïve at base-
line and the unexposed the non-naïves. The IRRs were estimated for confirmed dengue symp-
tomatic cases, confirmed chikungunya symptomatic cases, confirmed Zika cases and overall
dengue infections. The IRR for total dengue infections and symptomatic Zika cases were sig-
nificant using the Logrank test (Table 8). More confirmed Zika cases were detected in dengue
naïves and more confirmed chikungunya cases were detected in dengue non-naïves (Table 8).
Table 6. Incidence rates (IR) per 1,000 person-years of dengue infections in the cohort in Yucatan, Mexico by age,
gender, and city (N = 1,890).
Person-years at risk (N) Dengue infections IR (95%CI)
All participants 2271(1890) 83 36.55 (29.3, 45.1)
Age (Years)
� 8 692.84 (624) 35 50.5 (35.7, 69.5)
9–14 359.74 (305) 17 47.3 (28.5, 74.1)
15–19 92.91 (76) 9 96.9 (47.2, 177.8)
20–49 959.68 (757) 23 23.9 (15.6, 35.4)
� 50 166.11 (128) 5 30.1 (11.0, 66.7)
Gender
Male 984.49 (882) 27 27.4 (18.4, 39.4)
Female 1286.79 (1008) 62 48.2 (37.3, 61.4)
City
Merida 1248.14 (1032) 51 40.9 (30.7, 53.3)
Progreso 481.76 (401) 27 56.1 (37.7, 80.4)
Ticul 540.38 (457) 11 20.4 (10.7, 35.4)
Prior exposure to dengue
Naïve 645.80 (542) 74 114.6 (90.6, 143)
Non-naïve 1625.20 (1348) 9 5.5 (2.7, 10.1)
https://doi.org/10.1371/journal.pntd.0006847.t006
Table 7. Seroconversion in the dengue-naïve participants at baseline in the first annual follow-up of the cohort in
Yucatan, Mexico (n = 555).
Merida (n = 302) Progreso (n = 162) Ticul (n = 91) Total
Seroconversion in naïves
Yes 43 (14.2%) 24 (14.8%) 7 (7.7%) 74 (13.3%)
No 259 (85.8%) 138 (85.2%) 84 (92.3%) 481 (86.7%)
https://doi.org/10.1371/journal.pntd.0006847.t007
Table 8. Incidence rate ratios for all arbovirus infections in the first annual follow-up of the cohort in Yucatan,
Mexico.
Event IRR (95%CI) Logrank
Dengue confirmed cases 1.4 (0.47, 4.14) p = 0.539
Dengue total infections 22.2 (11.13, 44.18) p = 0.001
Chikungunya confirmed cases 0.5 (0.21,1.24) p = 0.114
Zika confirmed cases 3.7 (1.06, 13.26) p = 0.041
Any arboviral infection 0.9 (0.49, 1.61) p = 0.625
https://doi.org/10.1371/journal.pntd.0006847.t008
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Confirmed Zika cases were 3.7 times more likely in dengue naïve compared to non-naïve
people. Also, for dengue total infections were 22.2 times more likely in dengue naïves com-
pared to non-naïves. The incidence rate ratios by city and age can be found in the supplemen-
tal materials.
Survival model for dengue infections
A Cox proportional hazard model was fitted for total dengue infections. The variables included
in the model were: age, prior exposure to dengue, gender, city, household size of five or more
people, and one or more infections in the same household. In the univariate analysis, age as a
continuous variable was significant as a protective factor for dengue infections (HR = 0.98,
95%CI: 0.96, 0.99). There was no significant association between total dengue infections and
overcrowding in the household but the remaining variables were significantly associated with
having a dengue infection. The highest hazard ratios were estimated for baseline exposure to
dengue (HR = 20.5, 95%CI: 10.30, 40.91) and having more people infected with dengue in the
household (HR = 57.9, 95%CI:37.21, 90.08). Those two variables were included in the final
model as potential confounders. In the final model, having a dengue infection during the first
year of follow-up was significantly associated with female gender, living in Ticul or Progreso,
and being dengue naïve at baseline. Age was not significantly associated with the outcome, as
it was confounded by prior immunity to dengue that increases with age. (Table 9).
Discussion
To our knowledge this is the first prospective cohort study to describe the incidence rates of
laboratory confirmed acute dengue and other arboviral infections in a population of healthy
individuals in the state of Yucatan, Mexico. Our results confirm sustained dengue transmis-
sion and also the emergence of other arbovirus (chikungunya virus and Zika virus) since 2015
in the state of Yucatan. This cohort enrolled 767 families (3,400 participants) from three cities
of the state of Yucatan, Mexico. The 3,400 participants contributed 3,480 person-years during
the first year of follow-up. The estimated dengue baseline seroprevalence of the cohort was
Table 9. Hazard ratios for total dengue infections in the first year of follow-up of the cohort in Yucatan, Mexico.
Variable Hazard ratio (95%CI)
Age
� 8 Ref Ref
9–14 1.06 0.59, 1.89
15–19 1.77 0.79, 3.96
20–49 1.27 0.72, 2.24
� 50 1.17 0.44,3.09
Gender
Males Ref Ref
Females 1.65 1.04, 2.62
City
Merida Ref Ref
Ticul 7.17 3.12, 16.49
Progreso 2.04 1.12, 3.76
Baseline status
Dengue non-naïve Ref Ref
Dengue naïve 15.35 7.19, 33.08
https://doi.org/10.1371/journal.pntd.0006847.t009
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70.28%. The city with the higher seroprevalence was Ticul (81.07%), followed by Merida and
Progreso and these seroprevalences increased with age as expected for dengue endemic trans-
mission settings. It is important to highlight that the seroprevalence in the age group from
9–14 years old in the three study settings were� 70% and these findings could be relevant for
the Mexican government to guide policies for dengue vaccine introduction.
Most of the dengue cohorts in Latin America and South East Asia are pediatric cohorts [29,
35, 37, 38, 45, 51–54]. Our cohort and the cohort from Iquitos, Peru have similar design, both
have participants from all age groups and active surveillance was done at schools [55, 56]. Our
cohort provides the opportunity to collect prospective data in all ages to understand better the
full burden of dengue and other arboviruses that have emerged in the region.
The symptoms from the arboviral infections detected during the first year of follow-up
were very similar which is why the clinical diagnosis might not be accurate. It is necessary to
confirm the suspected cases in order to know which viruses are circulating in these endemic
areas. The incidence rate of arboviral suspected cases was 58.2 per 1,000 person years. The den-
gue incidence rate for suspected cases was 21.86 per 1,000 person-years (95%CI 17.32, 27.25)
and falls in the confidence interval of incidence rates estimated in the Nicaraguan dengue
cohort [29, 57, 58].
The incidence rates of confirmed symptomatic Zika and confirmed chikungunya were
2.33 cases per 1,000 person-years and 8.74 cases per 1,000 person-years respectively. One case
with co-infection of dengue and chikungunya was also detected as in some other endemic
countries with co-circulation of multiple arbovirus [59]. The incidence rate of confirmed
symptomatic dengue infections was 3.49 per 1,000 person-years. This proportion of confirma-
tion and the incidence were lower than these estimates in other dengue cohorts [29, 35, 37, 38,
45, 51–54, 60].
One explanation is that during the first year of follow-up chikungunya virus was introduced
in the state of Yucatan and these arboviruses that are transmitted by Aedes aegypti compete in
the mosquito causing lower circulation of the other arbovirus in this case dengue. [61–64]
From the original cohort a total of 1,096 (32.2%) participants did not complete the activities
of the first year of follow-up but 2,304 are still being followed from the original cohort. The
mobility on the population in Yucatan was higher than we anticipated so assessing potential
mobility will be important for the future of the cohort.
The analysis of the dengue infections was done in 1,890 participants who had a baseline and
completed the first year of follow-up. The incidence rate for dengue infections was 36.55 infec-
tions per 1,000 person-years. This incidence rate is lower compared with other cohorts around
the world but it concurs with the low transmission of dengue during this first-year of follow-
up and the emergence of chikungunya in the state of Yucatan [29, 35, 37, 38, 45, 51–54, 60].
The highest incidence of dengue was observed in the participants in the group from 15-19
years of age followed by the� 8 year-olds. The group from 15-19 years of age is just 4.65% of
the cohort and only 25.64% of them were naïve at baseline. More participants from this age
group have been enrolled in the last months so it is expected to have better denominators for
the next years of follow-up.
Among 829 participants who were naïve at baseline, 555 (66.94%) completed the first year
of follow-up. In the naïves, there were 74 confirmed dengue infections for an overall serocon-
version rate of 13.33%. The incidence rate on primary infections was 114.59 per 1,000 person-
years. This rate is very similar to estimates from other dengue prospective cohorts in endemic
areas [29, 35].
Confirmed Zika cases were 3.7 times more likely in dengue naïve compared to non-naïve
people. Also, dengue total infections were 22.2 times more likely in dengue naïves compared
to non-naïves, this could be a reflection of inapparent infections that were missed in the
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population, and/or secondary infections that were not detected. The other incidence rate ratios
estimated were not significant. This is a very interesting finding given the current interest in
potential cross protection of dengue and Zika antibodies. It may be that recent, within two
years, dengue infection may be protective against symptomatic Zika. Our results are consistent
with recent publications available on this topic but do not prove the cross-protection and
more research needs to be done [65, 66].
The hazard ratios estimated for dengue infections during the first year of follow-up were
significant for females, participants living in Ticul or Progreso, one or more infections con-
firmed in the household, and being dengue naïve at baseline. In the final model after control-
ling for baseline dengue status age was not significantly associated with the outcome. To our
knowledge, this is the first dengue cohort study that uses survival analysis as a tool to better
understand the transmission dynamics of dengue and other arbovirus.
The limitations of this study include ascertainment of cases through enhanced passive sur-
veillance. Thus, some dengue cases may not have been detected due to participants not seeking
healthcare. Another limitation is that serum samples for cohort-wide serological testing are
only available for participants once per year so it will be better to have more seroprevalence
data points in time but logistically this is difficult to manage. We did not test the yearly samples
for inapparent infections for CHIKV and ZIKV given that it was not planned on the original
protocol and also due to the cross-reactivity of DENV and ZIKV with the currently available
serological assays. Also we did not use paired samples in all the symptomatic arboviral cases;
this decision was made with the advise of the arbovirus State Laboratory of Yucatan. This
study relies on Inhibition ELISA to assess inapparent infections. The gold standard to assess
DENV infection is the plaque reduction neutralization test (PRNT) but it is very labor inten-
sive and expensive so testing all the participants was not feasible.
Over the last five decades, dengue has emerged as a major health problem in the tropical
regions worldwide including Latin America and the Caribbean [2, 10, 22, 36]. More recently
chikungunya and Zika virus emerged in the Americas causing significant epidemics in
most of the countries infested with Aedes aegypti [67–70]. Mexico is considered one of the
endemic dengue countries in the region and since 2015 with the emergence of chikungunya
and Zika virus, the three arboviruses have been co-circulating in many areas of the country
[71–73].
In summary, this study reported baseline seroprevalence, incidence of dengue infections,
dengue cases and other arboviral cases in a community-based cohort from three settings in
Yucatan, Mexico using analytic methods. This is the first report of the results from this pro-
spective cohort that allowed to determine the incidence of arboviral infections and to estimate
the true rate of disease, which is usually underestimated by passive surveillance. These data
will be used to estimate disease burden. The incidence estimates will be useful for policy mak-
ers and to evaluate interventions like vector control strategies and vaccines. Future analysis of
household transmission, cluster analysis and effectiveness of interventions are planned.
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